Cortexin vs Liraglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cortexin
Cortexin is a polypeptide complex derived from pig brain cortex, used clinically in Russia and Eastern Europe for neurological conditions including stroke recovery, traumatic brain injury, and cognitive decline.
Full details →Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →Side-by-Side Comparison
| Aspect | Cortexin | Liraglutide |
|---|---|---|
| Mechanism | Contains a mixture of neuropeptides and amino acids that support neuronal metabolism, provide neuroprotection, and enhance synaptic transmission. Specific mechanisms not fully characterized. | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. |
| Typical Dosage | Clinical protocols: 10mg intramuscularly once daily for 10-20 days. May be repeated after 3-6 month interval. | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. |
| Administration | Intramuscular injection. Comes as lyophilized powder requiring reconstitution. Treatment given in courses rather than continuously. | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. |
| Side Effects | Generally well-tolerated. May cause injection site reactions or mild allergic responses in sensitive individuals. | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. |
| Best For |